Tenderwize
Wróć do wyszukiwania

Non-exclusive Drug Discount Agreement for Aripiprazole (Parenteral)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Mar 31, 2027 · 216 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Aripiprazol für die parenterale Applikation (ATC-Code nach WHO: N05AX12)

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

20 / 100

Czynniki ryzyka

No guaranteed volume; actual sales depend on prescription and pharmacy behavior, leading to unpredictable revenue.

Early termination risk: buyer may cancel the Open House if exclusive agreements are made (typically 8-12 months after p...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Mar 2027
  • Conclusion of non-exclusive discount agreements for Aripiprazole parenteral products
  • Supply of pharmaceutical products to AOK PLUS for patients in Saxony and Thuringia
Pokaż pełne podsumowanie

This Open House model tender by AOK PLUS seeks non-exclusive discount agreements under §130a Abs. 8 SGB V for the active substance Aripiprazole for parenteral administration (ATC N05AX12). The framework agreement is open to all eligible pharmaceutical companies meeting participation requirements. No exclusivity, no minimum purchase quantities, and no estimated value are provided. The contract runs until 31 March 2027. Submissions are accepted periodically, with the first deadline on 5 March 2025. The procedure is not subject to public procurement law; the notice is published for transparency. All communication and document access are via the DTVP portal, with strict confidentiality required.

Ryzyka

No guaranteed volume; actual sales depend on prescription and pharmacy behavior, leading to unpredictable revenue.

Early termination risk: buyer may cancel the Open House if exclusive agreements are made (typically 8-12 months after p...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Must be a pharmaceutical company as defined by §4 Abs. 18 AMG for the offered products

Eligibility

  • Submit self-declaration on exclusion grounds (GWB §§123,124)

Administrative

  • Submit self-declaration regarding EU Russia sanctions (Art. 5k of Regulation 833/2014)

Wymagania mogą być niepełne.

Kryteria udzielenia

Lot 1

No explicit award criteria specified in the notice. Participation is open to all fulfilling conditions.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Aripiprazole (Parenteral)

Framework agreement for non-exclusive discount agreements on Aripiprazole parenteral formulations. Open House model; no exclusivity, no guaranteed volumes. Contract ends 31 March 2027.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Mar 2025 - Mar 2027

Kategoria

Pharmaceutical products

Kryteria udzielenia

No explicit award criteria specified in the notice. Participation is open to all fulfilling conditions.

Termin

Deadline Mar 31, 2027

Szczegóły zamówienia

Data publikacji
22 Jan 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
48010-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3